Ironwood Q1 2023: net income $45.7M ($0.30 EPS); LINZESS demand up 10% YoY

IRONWOOD PHARMACEUTICALS INC

2023-Q1 EPS reported $0.25 revenue$104,061,000

Total revenues $104.1M, up 7% YoY; GAAP net income $45.7M vs $38.8M.
LINZESS U.S. net sales $250M (+8% YoY); prescription demand grew 10% YoY.
Ended Q1 with $740M cash; full-year 2023 financial guidance maintained.
PDUFA date June 14 for potential pediatric functional constipation indication in ages 6-17.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRONWOOD PHARMACEUTICALS INC reported first quarter 2023 results: revenue $ 104,061, net income 45,714, EPS 0.30. Guidance reaffirmed.

Period: first quarter 2023
Revenue: $ 104,061
Net income: 45,714
EPS: 0.30
Guidance: reaffirmed
Result: reported results

Exact text from the filing

supporting the next growth horizon for the company.” First Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) 1Q 2023 1Q 2022 Total revenues $ 104,061 $ 97,529 Total operating expenses 43,964 39,683 GAAP net income 45,714 38,801 GAAP net income per share – basic 0.30 0.25 GAAP net income per share –diluted 0.25 0.21 Adjusted

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-055770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.